A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies

Cancer
Constantine S TamJohn F Seymour

Abstract

Fludarabine-containing combination chemotherapy regimens are increasingly used in the treatment of indolent lymphoid malignancies, with the associated risk of infection being the major toxicity. Predictors of infection during fludarabine-containing combination therapy are poorly defined and optimal strategies for infection prophylaxis are not known. The authors analyzed their experience with patients treated with the fludarabine-mitoxantrone (FM) or fludarabine-cyclophosphamide (FC) regimens to develop a predictive model for infections. Ninety-two patients with indolent lymphoid malignancies were treated with FM (n = 29) or FC (n = 63). Baseline variables including age, gender, regimen, disease histology, previous therapy, time from diagnosis to current treatment, performance status, renal function, absolute neutrophil count (ANC), lymphocyte count, and immunoglobulin G levels were examined retrospectively for their association with risk of infectious complications during or within 4 weeks of therapy. Six risk factors were associated with infectious complications: age > 60 years, > or = 3 previous therapies, previous fludarabine exposure, time from diagnosis to current treatment of > 3 years, performance status > or = 2, and ba...Continue Reading

References

Jan 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H S HochsterM J O'Connell
Mar 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinM Keating
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P Solal-CélignyM Leporrier
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinF Cabanillas
Oct 3, 1998·Annals of Internal Medicine·E J AnaissieM J Keating
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P L ZinzaniS Tura
Mar 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H S HochsterP A Cassileth
Sep 21, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C R CrawleyT A Lister
Oct 21, 2000·Mayo Clinic Proceedings·S TsiodrasD P Kontoyiannis
Dec 15, 2000·The New England Journal of Medicine·K R RaiC A Schiffer
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M O'BrienM Keating
Oct 6, 2001·Blood·M LeporrierUNKNOWN French Cooperative Group on Chronic Lymphocytic Leukemia
Jan 5, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J F SeymourR M Fox
Jul 27, 2002·Clinical Lymphoma·Barbara SchmittMichael Hallek
Dec 11, 2002·British Journal of Haematology·Francesc BoschUNKNOWN GELCAB (Grup per l'Estudi dels Limfomes a Catalunya i Balears)
Jun 13, 2003·European Journal of Haematology·Ettore Mariano SchiavoneFelicetto Ferrara
Jan 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ralf HeroldGünter Henze
May 26, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pier Luigi ZinzaniMichele Baccarani
Jun 16, 2004·Cancer·Apostolia M TsimberidouSusan O'Brien

❮ Previous
Next ❯

Citations

Jul 7, 2010·Nature Reviews. Clinical Oncology·Constantine S Tam, Michael J Keating
Apr 29, 2005·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Robert Tamburro
Sep 13, 2014·Leukemia & Lymphoma·Nimish ShahSimon Rule
Aug 21, 2007·International Journal of Antimicrobial Agents·Georg Maschmeyer, Antje Haas
Mar 22, 2006·Seminars in Hematology·Razelle Kurzrock, Farhad Ravandi
Jul 8, 2009·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Ewa Lech-MarandaTadeusz Robak
Jan 11, 2005·Clinical Journal of Oncology Nursing·Fran West, Sandra A Mitchell
Aug 5, 2010·Clinical Journal of Oncology Nursing·Kena C MillerAsher Chanan-Khan
Jul 31, 2007·Drugs·Vanessa R Anderson, Caroline M Perry

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.